カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の卵巣がん治療薬市場（2023-2030）：治療クラス別（PARP、PD-L1、血管新生阻害剤）、治療法別、最終用途別、地域別

【英語タイトル】Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Treatment, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV279）・商品コード：GRV23NOV279
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：94
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

卵巣がん治療薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、卵巣がん治療薬の世界市場規模は、2023年から2030年にかけて年平均成長率6.6%を記録し、2030年までに56億5000万米ドルに達する見込みです。同市場の成長は、新薬の採用増加や強力なパイプラインの存在といった要因によるところが大きいです。高齢者人口の増加や不健康な生活習慣による卵巣癌の罹患率の上昇が、市場を押し上げています。

卵巣がんは、女性の悪性腫瘍全体の3.0%、がんによる女性死亡者全体の6.0%を占めています。卵巣がんは2016年に世界で235,200人の新規患者と140,000人の死亡者を占め、発生率は北米と欧州で最も高いと報告されています。

プラチナ製剤を使用しないPARP阻害剤とVEGF阻害剤の2次治療および3次治療の導入により、卵巣がんの治療方針は劇的に変化しました。開発中の抗体薬物複合体（ADC）を含むいくつかの生物学的製剤や低分子療法は、卵巣癌の治療スペクトラムに大きな影響を与えると推定されています。

卵巣がん治療薬市場レポートハイライト

- 治療法に基づくと、病院薬局セグメントが2022年に45.37%の最大売上シェアを獲得しました。がん研究・治療に対する政府の取り組みや資金提供の増加が薬剤開発とアクセシビリティを促進し、効果的な卵巣がん治療薬が病院環境で利用できるようになっています。用途別では、商用セグメントが2022年に88.0%の最大の売上シェアを占めています。これは、ジェネリック医薬品に対する需要の高まりによるもので、慢性疾患の負担が大きいことも成長の一因となっています。

- 例えば、オーストラリア連邦によると、2020年にオーストラリア政府は卵巣がん対策に特化した8つの研究プロジェクトに1,620万米ドルを割り当てました。オーストラリアでも世界全体でも、卵巣がんはすべての女性がんの中で一貫して最低の生存率を維持しています。平均すると、卵巣がんと診断された女性100人中43人が、診断から5年後に生存しています。

- 予測期間中、CAGR 8.1%で最も急成長が見込まれるのはオンライン薬局部門です。オンライン薬局が卵巣がん治療薬の注文や患者の自宅への配送を容易にし、特に健康上の制約がある患者の自宅への配送を容易にするという利便性が、卵巣がん治療薬市場におけるオンライン薬局セグメントの大きな促進要因となっています。このアクセシビリティは、必要不可欠な薬剤を入手する際の障壁をなくし、患者の治療レジメンへのアドヒアランスを高め、これらの薬剤の市場リーチを拡大します。

- 例えば、AdooQ BioScience社は、顧客が卵巣がん治療薬、特にルカパリブを注文するのに便利なプラットフォームを提供しています。ウェブページでは、薬剤の名称、説明、剤形、価格などの詳細情報にアクセスすることができます。

- 北米における卵巣癌の罹患率の高さは、この地域の卵巣がん治療薬市場の主要な促進要因であり、効果的な治療法に対する継続的で大きな需要をもたらしています。

- 例えば、米国癌協会による2023年の米国における卵巣癌の推計によると、約19,710人の女性が新たに卵巣癌と診断され、約13,270人の女性が卵巣癌で命を落とすと予測されています。-

- アジア太平洋地域では臨床試験への参加が増加しており、卵巣がん患者が最先端の治療を受けられるだけでなく、製薬企業や研究者を惹きつけることで医薬品開発が促進され、同地域の卵巣がん治療薬市場が発展しているため、予測期間中の CAGR は 8.0%と最速となる見込みです。

- 例えば、Clinical Trials Arenaによると、2017年から2022年にかけて、アジア太平洋地域では臨床試験が約10%増加し、米国や欧州などの他の主要地域で観察された成長率を上回りました。同地域のこの成長は、同期間の全体平均である年率5.3%を大幅に上回っています。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. 世界の卵巣がん治療薬市場：治療クラス別予測・動向分析
第5章. 世界の卵巣がん治療薬市場：最終用途別予測・動向分析
第6章. 世界の卵巣がん治療薬市場：治療法別予測・動向分析
第7章. 世界の卵巣がん治療薬市場：地域別予測・動向分析
第8章. 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapeutic Class
1.1.2. Treatment
1.1.3. End-use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapeutic class outlook
2.2.2. Treatment outlook
2.2.3. End-use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Ovarian Cancer Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Ovarian Cancer Drugs Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Ovarian Cancer Drugs: Therapeutic Class Estimates & Trend Analysis
4.1. Ovarian Cancer Drugs Market: Key Takeaways
4.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. PARP Inhibitors
4.3.1. PARP inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Angiogenesis inhibitors
4.4.1. Angiogenesis inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. PD-L1 inhibitors
4.5.1. PD-L1 inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Ovarian Cancer Drugs: End-use Estimates & Trend Analysis
5.1. Ovarian Cancer Drugs Market: Key Takeaways
5.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Hospital Pharmacy
5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Retail pharmacy
5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Online Pharmacy
5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Ovarian Cancer Drugs: Treatment Estimates & Trend Analysis
6.1. Ovarian Cancer Drugs Market: Key Takeaways
6.2. Ovarian Cancer Drugs Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Chemotherapy
6.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Radiation Therapy
6.4.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Hormonal Therapy
6.5.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Targeted Therapy & others
6.6.1. Targeted therapy & others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Ovarian Cancer Drugs Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Ovarian Cancer Drugs Market by Region: Key Takeaway
7.3. North America
7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.2. U.S.
7.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.3.3. Canada
7.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.2. Germany
7.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.3. France
7.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.4. Italy
7.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.5. Spain
7.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.6. Sweden
7.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.7. Norway
7.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.4.8. Denmark
7.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.2. China
7.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.3. India
7.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.4. Australia
7.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.5. Thailand
7.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.5.6. South Korea
7.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.2. Mexico
7.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.6.3. Argentina
7.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7. MEA
7.7.1. Saudi Arabia
7.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.2. South Africa
7.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.3. UAE
7.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
7.7.4. Kuwait
7.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
8.2.1. AbbVie Inc.
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Pfizer, Inc.,
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. AstraZeneca,
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. F. Hoffmann-La Roche AG,
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Johnson & Johnson Services, Inc.,
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Boehringer Ingelheim International GmbH,
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Clovis Oncology,
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. ImmunoGen, Inc.
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Vivesto AB
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviations
Table 2 North America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 3 North America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 4 North America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 5 North America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 6 U.S. ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 7 U.S. ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 8 U.S. ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 9 Canada ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 10 Canada ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 11 Canada ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 12 Europe ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 13 Europe ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 14 Europe ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 15 Europe ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 16 Germany ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 17 Germany ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 18 Germany ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 19 UK ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 20 UK ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 21 UK ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 22 France ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 23 France ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 24 France ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 25 Italy ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 26 Italy ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 27 Italy ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 28 Spain ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 29 Spain ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 30 Spain ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 31 Sweden ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 32 Sweden ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 33 Sweden ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 34 Norway ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 35 Norway ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 36 Norway ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 37 Denmark ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 38 Denmark ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 39 Denmark ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 40 Asia Pacific ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 41 Asia Pacific ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 42 Asia Pacific ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 43 Asia Pacific ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 44 China ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 45 China ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 46 China ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 47 Japan ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 48 Japan ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 49 Japan ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 50 India ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 51 India ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 52 India ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 53 Thailand ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 54 Thailand ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 55 Thailand ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 56 South Korea ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 57 South Korea ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 58 South Korea ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 59 Latin America ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 60 Latin America ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 61 Latin America ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 62 Latin America ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 63 Brazil ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 64 Brazil ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 65 Brazil ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 66 Mexico ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 67 Mexico ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 68 Mexico ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 69 Argentina ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 70 Argentina ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 71 Argentina ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 72 Middle East and Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 73 Middle East and Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 74 Middle East and Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 75 Middle East and Africa ovarian cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 76 South Africa ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 77 South Africa ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 78 South Africa ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 79 Saudi Arabia ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 80 Saudi Arabia ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 81 Saudi Arabia ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 82 UAE ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 83 UAE ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 84 UAE ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)
Table 85 Kuwait ovarian cancer drugs market, by therapeutic class, 2018 - 2030 (USD Million)
Table 86 Kuwait ovarian cancer drugs market, by treatment, 2018 - 2030 (USD Million)
Table 87 Kuwait ovarian cancer drugs market, by end-use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Ovarian cancer drugs: Market outlook
Fig. 9 Ovarian cancer drugs: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Ovarian cancer drugs market driver impact
Fig. 15 Ovarian cancer drugs market restraint impact
Fig. 16 Ovarian cancer drugs market strategic initiatives analysis
Fig. 17 Ovarian cancer drugs market: Therapeutic Class movement analysis
Fig. 18 Ovarian cancer drugs market: Therapeutic Class outlook and key takeaways
Fig. 19 PARP inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Angiogenesis inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 PD-L1 inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Ovarian cancer drugs market: Treatment movement analysis
Fig. 23 Ovarian cancer drugs market: Treatment outlook and key takeaways
Fig. 24 Hospital pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Online pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Ovarian cancer drugs market: End-use movement analysis
Fig. 28 Ovarian cancer drugs market: End-use outlook and key takeaways
Fig. 29 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Hormonal therapy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Targeted therapy & others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Global ovarian cancer drugs market: Regional movement analysis
Fig. 34 Global ovarian cancer drugs market: Regional outlook and key takeaways
Fig. 35 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

★調査レポート[世界の卵巣がん治療薬市場（2023-2030）：治療クラス別（PARP、PD-L1、血管新生阻害剤）、治療法別、最終用途別、地域別] (コード：GRV23NOV279)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の卵巣がん治療薬市場（2023-2030）：治療クラス別（PARP、PD-L1、血管新生阻害剤）、治療法別、最終用途別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の女性健康診断市場（2023-2030）：最終用途別、用途別（癌、感染症、骨粗鬆症、妊娠・不妊、出生前）、地域別
  • 世界の糖尿病性足潰瘍治療市場2024-2030：治療法別（生物学的製剤、治療機器）、潰瘍種類別（虚血性、神経障害性）、最終用途別（病院、ASC）、地域別
  • 卵巣がん治療薬のグローバル市場（～2030）：血管新生阻害剤、PARP阻害剤、PD-L1阻害剤
  • 世界のソフトジェルカプセル市場（2023-2030）：種類別（ゼラチンベース／動物性、非動物性）、用途別、最終用途別、地域別
  • 世界のスキンケアデバイス市場（2023-2030）：製品別、用途別（診断デバイス、治療デバイス）、最終用途別、地域別
  • 世界の湿潤創傷被覆材市場（2023-2030）：製品別（フォーム被覆材、フィルム被覆材）、用途別、最終用途別、地域別
  • 世界の光線療法機器市場（2023-2030）：製品別（従来型光線治療器）、用途別（皮膚疾患治療）、最終用途別、地域別
  • 世界の製薬用協働ロボット市場（2023-2030）：用途別（ピッキング＆パッケージング、ラボ用）、最終用途別（製薬会社、研究所）

    • ◆H&Iグローバルリサーチのお客様（例）◆